Aquinox Pharmaceuticals Inc. — biopharmaceutical company engaged in the discovery and development targeted treatments in the area of inflammatory and immuno-oncology. The company was founded in 2003, its headquarters is located in Vancouver (Canada).

Aquinox’s leading drug candidate is AQX–1125 — small molecule activator of SHIP1 enzyme, which plays a key role in inflammation. In 2016 Aquinox begins phase III clinical trials for this drug candidate to treat bladder pain syndrome/interstitial cystitis — a chronic disease, which affects millions of people. The company puts a lot of hope on AQX–1125, moreover, the current clinical trials show good results.

Our forecast for stock prices: $ 16.
Learn how to invest in this company. Our experts will provide you all necessary support. Submit your application.
You can order more detailed analysis on the company, which includes: